Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from Chardan Capital

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $2.00 price target on the stock.

A number of other analysts have also recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Benchmark decreased their target price on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Trading Up 11.1%

Shares of Reviva Pharmaceuticals stock opened at $0.31 on Monday. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17. The firm has a market capitalization of $35.67 million, a price-to-earnings ratio of -0.67 and a beta of 0.08. The firm’s 50 day simple moving average is $0.52 and its two-hundred day simple moving average is $0.49.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.05. On average, sell-side analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals in the 2nd quarter worth approximately $1,026,000. 683 Capital Management LLC acquired a new position in shares of Reviva Pharmaceuticals in the 2nd quarter valued at $381,000. Persistent Asset Partners Ltd boosted its holdings in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares in the last quarter. Millennium Management LLC grew its position in Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares during the period. Finally, Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals in the third quarter valued at $37,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.